Respiratory syncytial virus: concerns and control.
McCarthy
Carol A
CA
Pediatric Infectious Disease, Maine Medical Center, USA.
Hall
Caroline Breese
CB
D000368:Aged; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000914:Antibodies, Viral / Q000627:therapeutic use; D000998:Antiviral Agents / Q000627:therapeutic use; D002648:Child; D002675:Child, Preschool; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use; D007223:Infant; D000069455:Palivizumab; D018357:Respiratory Syncytial Virus Infections / Q000150:complications / Q000175:diagnosis / Q000628:therapy*; D022261:Respiratory Syncytial Virus Vaccines; D012136:Respiratory Syncytial Viruses / Q000276:immunology
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000914:Antibodies, Viral; D000998:Antiviral Agents; D016756:Immunoglobulins, Intravenous; D022261:Respiratory Syncytial Virus Vaccines; C098685:respiratory syncytial virus immune globulin intravenous; D000069455:Palivizumab